Scrip

Lupin has followed Sandoz and Sun Pharma in settling antitrust litigation with US insurance giant Humana on alleged price-fixing. This $30m settlement denies all allegations and does not imply admission of liability, but could more settlements follow?

Scrip >>Leadership >>Executive Moves Executives On The Move: Ailux Gets A New CSO From AstraZeneca Recent changes in the industry include board appointments at Avalyn Pharma, Faron Pharmaceuticals and Telix Pharmaceuticals, plus a raft of new appointments at Ambrose Healthcare include a new chief of intellectual property from GSK.

Global Investors Provide 30% Of New Funding South Korean biotech’s successful funding buoyed by strong global investor interest and encouraging Phase II data for MASH contender DD01.

Multiple First-In-Class Pipeline Assets On the heels of Alphamab Oncology's anti-HER2 bispecific meeting its Phase III endpoint in early breast cancer, the Chinese firm's CEO shares pipeline development plans and R&D strategies.

Entries are now open for the 22nd Annual Scrip Awards Firmly established as best in class for pharma and biotech, the Scrip Awards will be held on Wednesday, Dec. 2, 2026, at the historic venue Raffles London at The OWO. Since their inception, the Scrip Awards has proudly celebrated the essential role the pharmaceutical, biotech and allied industries play in advancing healthcare.

Gears Up For Stock Listing This Year The Korean bioventure’s oversubscribed pre-IPO financing followed a $1bn global licensing deal with Sanofi and is set to support a planned KOSDAQ listing by the end of this year. Investors Express Strong Interest And Firm Intent To Invest (Shutterstock) South Korea’s ADEL has raised a higher-than-expected KRW49bn ($33.1m) in a pre-IPO financing round that it will use to further progress the development of its neurodegenerative disease assets.

The UK drugmaker thinks it could have another blockbuster drug on its hands with GSK going all in on its antibody-drug conjugate, Mo-Rez. GSK is betting on the success of its B7-H4 antibody-drug conjugate, (ADC) Mo-Rez, by pushing the drug directly into Phase III trials after it showed promising results in early studies in both platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC).

Cyclerion, Kezar, IO Biotech End Searches For Strategic Alternatives Restructuring Edition: Replimune said RP1 development is not viable without accelerated approval, so it is cutting jobs. Cyclerion Therapeutics, Kezar Life Sciences and Assertio announced reverse mergers or other acquisitions, while IO Biotech, Iterum and Lipella filed for bankruptcy.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements. • Source: Alamy The table above records the past week’s major catalyst events that occurred in the late-stage pipeline during the past week (see table for relevant dates), created using Citeline’s Biomedtracker.

2025 saw some shakeups to the sales rankings of big pharma, but with widespread major asset patent losses, 2026 and beyond could prove even more turbulent. • Source: Allan Swart / Alamy Stock Photo 2025 saw Eli Lilly storm up the ranks to become the biggest company in the world by annual pharmaceutical sales. Meanwhile Merck & Co, the second place company in 2024, saw a tumble down to seventh in 2025.